Vaxxas

Vaxxas is excited to announce that the company has secured a worldwide license from the The National Institutes of Health for a next-generation RSV vaccine antigen.    The license will allow #Vaxxas to prepare for clinical trials of the first needle-free RSV vaccine, delivered with Vaxxas' novel high-density microarray patch (HD-MAP) technology.    The next-generation vaccine antigen was developed and optimised by the NIH scientists to prompt a more robust and durable immune response against RSV when compared to the antigen already used in globally approved vaccines.    These advantages, combined with the potential benefits of Vaxxas’ HD-MAP technology including room-temperature stability and self-administration, could provide a vaccine that makes a significant impact to the way we protect populations against RSV in future.    Following preclinical development of the product, Vaxxas plans to progress its needle-free HD-MAP/RSV vaccine candidate to a Phase I clinical study.     Read the full story here: https://lnkd.in/g2uxM8qU     #Vaxxas #RSV #RSVVaccine #MedicalInnovation #GlobalHealth

We’re excited to be a part of Australia’s biggest week in biotech this week, with the Vaxxas team attending #AusbioInvest and #Ausbiotech in Melbourne!    📅 Join Vaxxas’ CEO David Hoey and other industry leaders at AusbioInvest at the Park Hyatt, Melbourne on Tuesday, 29 October    🔬🧪 Visit us at the Queensland Government stand (36 – 41) at Ausbiotech Melbourne Convention and Exhibition Centre from 30 October – 1 November.    💡🧬 Join #Vaxxas Chief Technology Officer Angus Forster when he joins Ausbiotech CEO Rebekah Cassidy and other industry leaders for a panel discussion on making medical manufacturing a part of a future made in Australia on Wednesday, 30 October.    👩🏻🔬👨🏻🔬 Catch-up with the Vaxxas team across the three-day event to discuss the latest advancements in our needle-free vaccine technology.    We look forward to seeing you there! Find out more here: AusBiotech 2024 https://lnkd.in/eBB_WT3   #AusBio24 #AusBiotech #biotechinnovation #unitedthroughinnovation

AusBiotech's annual AusBioInvest 2024 conference is almost here! Will you be attending?    Join Vaxxas’ CEO David Hoey and other industry leaders at Australia’s premier biotech investment conference on Tuesday, 29 October at the Park Hyatt Hotel in Melbourne, Australia.     AusBioInvest is designed to drive investment outcomes and foster collaboration in life sciences and medical research.    📅 Tuesday, 29 October 2024  11.05am – 12.00pm  Park Hyatt Hotel, Melbourne    Find out more and register your attendance here: https://lnkd.in/gtPca-7v    #AusBio #AusBioInv #InvestInHealth

Vaxxas’ Sarika Namjoshi, PhD, Head of Formulation and Analytical, is attending AAPS 2024 (American Association of Pharmaceutical Scientists (AAPS) | @aapscomms) #PharmSci360 this week in Salt Lake City, Utah.   Sarika is a Rapid Fire Speaker in the Preclinical, Clinical and Translational Science segment of the program, with her presentation Fomulation and Analytical Considerations for Assessing CQAs (critical quality attributes) of Microarray Patches   This is a great opportunity to learn more about how Vaxxas’ high-density microarray patch (HD-MAP) technology could transform the way #vaccines are delivered in future, and the critical considerations of formulation factors in the manufacturing process.   📅 Wednesday, 23 October 2024 3:30 PM – 3:45 PM MT Salt Place Convention Centre Salt Lake City, UT   AAPS PharmSci 360 is the world’s premier gathering of pharmaceutical scientists, and the only meeting covering the entire continuum of #pharmaceutical science, from discovery to delivery.   Find out more here: https://lnkd.in/dUc3fmAr   #MedicalInnovation #AAPS2024

Brisbane is buzzing with opportunity, and #Vaxxas is excited to be a part of its growth! 🚀     The 2024 State of the City Report by the Brisbane Economic Development Agency and Deloitte says Brisbane's booming economy, strategic connectivity to the Asia Pacific, and world-class education make it the perfect hub for businesses like ours to innovate and thrive.    It was great to join AmCham Australia, BEDA and so many others from across Brisbane’s vibrant business community last week at an event to discuss this report. Opened by Brisbane Lord Mayor Adrian Schrinner, Vaxxas Chief Technology Officer Dr Angus Forster then joined industry leaders BEDA CEO Anthony Ryan and Property Council of Australia QLD Executive Director Jess Caire for a panel discussion with other innovative Brisbane businesses Critical Care Research Group, Bechtel Corporation, Artemus Group, Howard Smith Wharves, and PsiQuantum.     From its global headquarters in Brisbane, Australia, Vaxxas is developing its high-density microarray patch (HD-MAP) technology which has the potential to transform the way #vaccines are delivered in the future.     Read more about the 2024 State of the City Report, and why Vaxxas is excited to be a part of Brisbane's thriving biotech and healthcare sector, in Forbes: https://lnkd.in/gfqKA3ER    #MedicalInnovation #GlobalHealth #HealthInnovation

Wrapping up a great week at OPTIONS XII for the Control of Influenza in Brisbane! The event not only gave us the chance to share exciting updates and results from our Phase I studies on COVID, seasonal flu, and pandemic flu, but also offered a great opportunity to reconnect with familiar faces and forge new connections across academia, industry, and government.   Highlights included:   🚀 A busy Vaxxas booth in the Exhibition Hall, showcasing our high-density microarray patch technology and its potential to transform the way life-saving vaccines are delivered in future.  👩🏻🔬 A deep dive into the key results from our Phase I COVID-19 study by Vaxxas’ Lead Scientist Kelly-Anne Masterman, PhD.  🦠 Latest results from our Phase I seasonal flu study presented by Vaxxas CTO Angus Forster during the Novel Vaccines and Platforms session. ✈️ Catching up with the two recipients of Vaxxas’ travel grant.   A big thank you to everyone who joined us – we look forward to continuing the conversation and advancing innovation in #globalhealth!   David Hoey Sarika Namjoshi, PhD Megan Polidano Sandra Depelsenaire Ben Baker David Muller Dan Devine Mai Gabr Preeti Pandey, PhD Tom Lake   #OPTIONS2024 #GlobalHealth #influenza

Are you attending OPTIONS XII for the Control of Influenza in Brisbane next week?   The largest scientific meeting focused on influenza, OPTIONS brings together leading researchers, practitioners, industry representatives and policymakers from around the world to advance our understanding of the impact #influenza and other respiratory diseases, such as COVID and RSV, have on global health.   Vaxxas is excited to be attending OPTIONS to discuss results and updates from its Phase I COVID, seasonal flu and pandemic flu studies using its novel vaccination technology, the high-density microarray patch (HD-MAP).   Here’s where you can catch the team next week:   🚀🚀 [Days 1 – 4] Visit the Vaxxas booth in the Exhibition Hall from Sunday, 29 September to Wednesday, 2 October.    👩🏻🔬👨🏻🔬 [Day 2] Join Vaxxas Scientist Kelly-Anne Masterman, PhD at the Poster Session on Monday, 30 September to learn more about the promising results from our Phase I study of the first needle-free COVID-19 vaccine [Great Hall, 630 – 830pm, Poster 71].    🦠 🔬 [Day 4] Join Vaxxas’ Chief Technology Officer Angus Forster on Wednesday, 2 October at the Novel Vaccines and Platforms session to hear, for the first time, results from our recent Phase I HD-MAP seasonal flu study [Mezzanine Room M1 and M2, 2:00 – 3:30pm].     We look forward to seeing you there!     Register here: https://lnkd.in/gcfBh5zy   #OPTIONS2024 #GlobalHealth #influenza

Thanks to Channel 7 News for its coverage of our recent announcement about the start of our largest Phase I clinical trial to date, assessing a needle-free avian flu vaccine patch with the US Government Biomedical Advanced Research and Development Authority (BARDA), as a potential future pandemic flu response. With potential benefits such as thermostability, reducing cold chain complexities, and ease of use, Vaxxas’ high-density microarray patch (HD-MAP) is designed to be rapidly and broadly deployed to accelerate vaccination uptake and rates, particularly when facing a future pandemic. Read the full story here: https://lnkd.in/ggDw5RSZ For more details on how you can get involved, visit: University of Sunshine Coast website: https://lnkd.in/gjZ4WFQu Doherty Clinical Trials website: https://lnkd.in/gEvQdbJk #PandemicPreparedness #PreventableHealth #Biotech

🏆 We’re proud to announce that our CEO David Hoey has been named a finalist for the 2024 AmCham Australia Alliance Awards in the #Biotechnology category!  The AmCham Alliance Awards, inaugurated in 2021, celebrate emerging and exceptional leaders in industries shaping the future economic collaboration between Australia and the United States. These fields include Artificial Intelligence, Biotechnology, Digital Economy, Clean Energy, Quantum, and Space. An Australian biotech company, Vaxxas is developing technology with the potential to transform the way vaccines are delivered, increasing vaccination rates and improving global health. Join us in congratulating David and all of this year’s finalists. Winners will be announced on 14 November at the Gala in Sydney.  Learn more here: www.amcham.com.au/gala2024 #Biotech #AmChamAllianceAwards #USAustraliaAlliance 

We’re thrilled to announce the initiation of Vaxxas' largest Phase I clinical trial to date, assessing a needle-free avian flu vaccine in collaboration with the US Government Biomedical Advanced Research and Development Authority (BARDA). The trial will enrol over 250 participants and take place over four trial centres in Melbourne and Queensland, comparing the safety and immune response of the vaccine delivered using Vaxxas’ proprietary needle-free vaccine technology, the high-density microarray patch (HD-MAP), as well as the needle and syringe. Vaxxas’ HD-MAP has shown potential in early studies to be easy to use, enable self-administration of vaccines, and keep vaccines stable at room temperature, reducing the usual complexities and costs associated with existing vaccine distribution and storage. We’re excited to be partnering with BARDA on this important initiative to expand its capabilities to respond to potential future pandemics, which aligns with #Vaxxas’ mission to improve #globalhealth through innovative vaccine delivery solutions. Learn more here: https://lnkd.in/gnq23pwe Interested in participating? Visit the clinical trial centres for more details: University of the Sunshine Coast Locations: South Bank; Moreton Bay; Sunshine Coast  Website: https://lnkd.in/gjZ4WFQu Doherty Clinical Trials Locations: East Melbourne  Website: https://lnkd.in/gEvQdbJk #PandemicPreparedness #AccessibleHealthcare #Biotech